POINT Biopharma Global Inc.
https://www.pointbiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From POINT Biopharma Global Inc.
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
Lilly Inks Follow-Up Radiopharmaceuticals Deal With Aktis
The big pharma will pay $60m upfront and make an equity investment in the Boston-based startup.
Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition?
With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.
Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout
The acquisition of Mariana will complement Novartis’s lutetium-based radioligand therapies with candidates using actinium. Lilly, Bristol and AstraZeneca all have made recent high-priced buys in the space.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice